STOCK TITAN

Protalix BioTherapeutics Inc. - PLX STOCK NEWS

Welcome to our dedicated news page for Protalix BioTherapeutics (Ticker: PLX), a resource for investors and traders seeking the latest updates and insights on Protalix BioTherapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Protalix BioTherapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Protalix BioTherapeutics's position in the market.

Rhea-AI Summary
Protalix BioTherapeutics, Inc. announced that its President and CEO, Dror Bashan, will present at the Canaccord Genuity 43rd Annual Growth Conference on August 9, 2023. The conference will be held from August 7-10, 2023 in Boston, MA. Mr. Bashan will provide a live corporate overview and the company's management will participate in one-on-one meetings with investors. The webcast of the presentation will be available for replay on the company's website for at least two weeks.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.87%
Tags
conferences
-
Rhea-AI Summary
Protalix BioTherapeutics, Inc. (PLX) to release Q2 2023 financial results and provide business update on August 7, 2023. The company will host a conference call and webcast at 8:30 a.m. EDT to discuss the results and recent developments. Investors can access the call toll-free or internationally, and a webcast will be available on the company's website. A replay will also be accessible for two weeks.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.61%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.43%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.55%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.32%
Tags
none
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.67%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.11%
Tags
none
Protalix BioTherapeutics Inc.

NYSE:PLX

PLX Rankings

PLX Stock Data

86.20M
64.48M
9.77%
14.03%
8.84%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
Israel
2 Snunit St Science Park Pob 455

About PLX

protalix is a publicly traded, clinical stage biopharmaceutical company (nyse, tase: plx) focused on the development and commercialization of recombinant therapeutic proteins using its proprietary procellex™ plant cell culture protein expression system. procellex provides a unique platform on which we have established a pipeline of proprietary and biosimilar versions of recombinant therapeutic proteins, relying upon known biological mechanisms of action. protalix's lead product, taliglucerase-alfa is an enzyme replacement therapy for the treatment of gaucher´s disease. protalix has concluded phase iii studies for this drug and is currently undergoing fda review. treatment is currently being provided by protalix to gaucher patients under clinical studies and companionate programs to hundreds of patients worldwide. this product has been licensed to pfizer. protalix's pipeline includes multiple therapeutic protein candidates including: acetylcholinesterase (biodefense); alfa‐galactosidase